BELLUS Health Inc. (BLU) PT Raised to $18 at BTIG; 'Best-case Scenario Reached'

BELLUS Health Inc (BLU) Launches $175M Share Offering in Canada and the US

BELLUS Health Inc. (Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the Supplement) to its short form base shelf prospectus dated December 23, 2020 (the Base Prospectus) in connection with a proposed public offering of its common shares of US$175 million (the Offering). The Supplement was filed with each of the securities regulatory authorities in the provinces of Canada. The Supplement and accompanying Base Prospectus were also filed with the U.S. Securities and Exchange Commission (the SEC) as part of a registration statement on Form F-­10, as it may be amended from time to time, in... More

Cowen Sets $15 PT on BELLUS Health Inc. (BLU)

Cowen analyst Ritu Baral reiterated an Outperform rating and set a $15.00 price target on BELLUS Health Inc. (NASDAQ: BLU) after the company's Ph2 SOOTHE trial of '5937 for rCC met stat sig on its primary endpoint of PBO-adjusted 24-hour cough reduction, with a... More

BELLUS Health Inc. (BLU:CN) (BLU) PT Raised to Cdn$16 at Bloom Burton & Co.

Bloom Burton & Co. analyst David Martin raised the price target on BELLUS Health Inc. (BLU:CN) (NASDAQ: BLU) to Cdn$16.00 (from Cdn$7.50) while maintaining a Buy (1) rating.

"Since 34% exceeds 23% substantially, we are increasing our target price to $16.00 based on 40% expected peak market share (previously... More

BELLUS Health (BLU) Stock Price Has Exploded 40% Today. Here's What Happened

Shares of Bellus Health (NASDAQ: BLU) are up more than 39% in todays trading session after the company presented positive topline results of BLU-5937 for the treatment of refractory chronic cough.

Bellus said that data showed a 34% placebo-adjusted reduction in 24-hour cough... More

BELLUS Health Inc (BLU) option implied volatility elevated into study

BELLUS Health Inc (NASDAQ: BLU) December call option implied volatility is at 520, January is at 230; compared to its 52-week range of 79 to 314 into Phase 2b SOOTHE study of BLU-5937 in refractory chronic cough. Call put ratio 1 call to 1 put.